SUMMARY The oral administration of mesalazine (5-aminosalicylic acid) resulted in the exacerbation of ulcerative colitis in two patients intolerant to sulphasalazine whose colitis had previously been quiescent. Although sulphasalazine intolerance is usually attributable to the sulphapyridine moiety, the possibility of salicylate sensitivity should be considered in colitic patients who fail to respond appropriately to sulphasalazine or who experience abdominal pain or diarrhoea while taking the drug.
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Mesalazine (Asacol, Tillotts Laboratories) is an oral 5-aminosalicylic acid coated with an acrylic based resin (Eudragit S) which is released in the terminal ileum and colon. It has a similar clinical effect to sulphasalazine in maintaining remission in patients with ulcerative colitis and its use has been advocated in patients intolerant of sulphasalazine.'' Exacerbation of diarrhoea and abdominal pain in patients receiving sulphasalazine for ulcerative colitis is unusual but well documented and has usually been attributed to the sulphapyridine moiety. 15 Ulcerative colitis, however, has been reported to be exacerbated by salicylate therapy alone.`We report two patients intolerant of sulphasalazine who developed a severe exacerbation of ulcerative colitis after the administration of 5-aminosalicylic acid. an effusion necessitated the withdrawal of sulphasalazine. Anaemia and colitic symptoms resolved after six weeks hospitalisation and he was discharged home. Follow up over the ensuing eight years was uneventful.
In June 1984, further hospitalisation and prednisolone therapy was necessitated by a relapse and on review in February 1985 he was asymptomatic. There was no antecedent history of atopy, asthma, eczema, or rhinitis. Mesalazine, 5-aminosalicylic acid, (Asacol) 400 mg tid was then introduced. Five days later, he developed a fever with severe bloody diarrhoea, nausea, and vomiting. Sigmoidoscopy releaved the macroscopic changes of an active colitis and an anal fissure. The withdrawal of mesalazine together with iv fluids resulted in a prompt clinical improvement and a normal temperature chart. Four days later mesalazine 400 mg tid was reintroduced and within 24 hours he had developed rigors, temperature 39.60 C, bloody diarrhoea, nausea, vomiting and an erythematous macular rash associated with mouth ulcers and synovitis of a wrist joint. Antibiotic and prednisolone therapy was introduced although he failed to improve until mesalazine was subsequently withdrawn.
Initial laboratory investigations revealed normal full blood count, liver function values and serum proteins. Eight days after the reintroduction of 5-aminosalicylic acid, however, the haemoglobin had fallen from g/dl to 8-4 g/dl with a normal differential count and reticulocyte count of 2%, the serum albumin had fallen from 39 g/1 to 25 g/1 and the 613 serum alkaline phosphatase and gamma glutamyl transferase had risen from 60 IU/l and 19 IU/l respectively to 144 IU/I and 104 IU/1. Viral and bacteriological screening tests were unremarkable and antinuclear antibodies were not detectable.
Two weeks after the introduction of prednisolone 40 mg/day and the withdrawal of mesalazine he was asymptomatic: prednisolone therapy was gradually withdrawn. Six months later, he remains asymptomatic.
Case 2
In April 1980, a 21 year old woman (EJ) was admitted to hospital with a four month history of lower abdominal pain, diarrhoea, anorexia, and weight loss. There was no antecedent history of atopy, asthma, eczema or rhinitis. The diagnosis of distal ulcerative proctocolitis was established on barium enema, sigmoidoscopy and rectal biopsy. Sulphasalazine therapy, 3 g/day, was withdrawn because of nausea, vomiting, and abdominal pain. After an uneventful recovery after prednisolone therapy 30 mg/day her symptoms remained well controlled over the ensuing three years on prednisolone therapy 5 mg/day.
In May 1983, she was readmitted with a severe exacerbation of colitis which responded well to oral and rectal prednisolone therapy. Sulphasalazine was gradually reintroduced and for four months, symptoms were well controlled without prednisolone therapy. Nausea, vomiting, abdominal pain and diarrhoea recurred, however, with sigmoidoscopic evidence of active colitis. Prednisolone therapy and the withdrawal of sulphasalazine resulted in good symptomatic control. In January 1984 while on prednisolone 10 mg daily, sulphasalazine desensitisation was attempted but nausea and diarrhoea recurred at a dosage of 500 mg daily. Because Laboratories-personal communication) .
The patients we describe may illustrate different phenomena. The first case developed an exacerbation of colitis in association with a generalised hypersensitivity reaction to 5-aminosalicylic acid whereas in the second case, diarrhoea and abdominal pain followed exposure to the drug without other evidence of hypersensitivity. Approximately one in five of patients reported to Tillotts Laboratories with diarrhoea in response to mesalazine had evidence of a generalised hypersensitivity reaction usually a fever and/or a skin rash. A similar experience has been well recorded in patients given para-aminosalicylic acid in the treatment of tuberculosis. Nausea, vomiting, and diarrhoea occur in 8% of such patients of whom less than one third experience allergic manifestations such as fever or skin rash.'2 Fever, skin rash and bloody diarrhoea have been reported in a patient given para-aminosalicylic acid."
Thus, although salicylate induced diarrhoea occurs with a spectrum of severity ranging from the nonspecific to florid hypersensitivity disorders, it is possible that there are overlapping subpopulations in whom allergic and idiosyncratic, dose related phenomena are involved. Proctocolitis has been shown to be exacerbated by acetylsalicylic acid in one atopic individual whose bowel symptoms could not subsequently be induced by sulphapyridine.' Nonsteroidal anti-inflammatory drugs have been shown to precipitate relapse in four patients with inactive ulcerative proctocolitis.' Studies examining analgesic ingestion in colitic patients before the onset of relapse compared with that of colitics in remission indicate a significantly higher prevalence of para-cetamol and salicylate ingestion before relapse. Such an association could be explained by the selective and idiosyncratic inhibitory effects of non-steroidal antiinflammatory drugs on mucosal prostaglandin synthesis and degradation.'
Although 5-aminosalicylic acid is a useful alternative therapy in most sulphasalazine intolerant patients, the possibility of salicylate sensitivity should be remembered in atopic individuals, patients who fail to respond appropriately to sulphasalazine and especially in patients who have previously experienced abdominal pain or diarrhoea while taking the drug.
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